SYRE Q2 2022 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$625,000-95.4% YoY

Gross Profit

$150,00024.0% margin

Operating Income

-$22M-3587.7% margin

Net Income

-$22M-3571.7% margin

EPS (Diluted)

$-6.79

QoQ Revenue Growth

-54.1%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$107M

Total Liabilities

$23M

Stockholders' Equity

$84M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$625,000	$14M	-95.4%
Gross Profit	$150,000	$117,000	+28.2%
Operating Income	-$22M	-$7M	-234.4%
Net Income	-$22M	-$7M	-226.8%